Breaking News

Atrium Therapeutics Launches with $270M

Aims to advance novel RNA medicines for rare genetic cardiomyopathies.

Author Image

By: Charlie Sternberg

Associate Editor

Atrium Therapeutics Inc. has launched as a newly independent, publicly traded company dedicated to delivering RNA therapeutics to transform care for people living with rare, life-threatening genetic cardiomyopathies. Atrium Therapeutics was established in connection with Avidity Biosciences Inc.’s acquisition by Novartis AG. The company is led by Kathleen Gallagher, President and Chief Executive Officer (CEO), and begins operations with two precision cardiology candidates, two undisclos...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters